Lingkai Zhang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.
Journal: Journal for immunotherapy of cancer
Published: May 05, 2026
Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.
Journal: Cancer
Published: February 10, 2026
Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.
Journal: British journal of cancer
Published: October 16, 2025
TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.
Journal: British journal of cancer
Published: July 24, 2025
ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2025
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.
Journal: Journal for immunotherapy of cancer
Published: December 13, 2024
TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma.
Journal: BMJ oncology
Published: August 24, 2024
Showing 1-8 of 8
Last Updated: 09/26/2026